Skip to main content

Table 1 Median survival of experiment mice (days)

From: In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine

 

HepG2 (n = 6)

A549 (n = 6)

HHCC (n = 6)

rM1H

60.5 ± 18.8

23 ± 4.9

19.5 ± 5.7

rM3H

30 ± 16.5

56 ± 13

29.5 ± 7.6

rMMH

58.5 ± 19.3*$

53 ± 15*^

29.5 ± 8.6*

PBS

19.5 ± 4.6

20.5 ± 3.7

25.5 ± 4.4

UnHuM

13 ± 3.3

12.5 ± 4.1

9.5

  1. In tumor challenge test, rMMH vaccinated mice presented the obvious survival time with HepG2 and A549 cells transplanting. Even in HHCC group the median survival of rMMH vaccinated mice was superior to others
  2. * p < 0.05 vs. PBS group and UnHuM group
  3. ^ p < 0.05 vs. rM1H
  4. $ p < 0.05 vs. rM3H group
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us